Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma

Cancer Science

Volumn 103, Issue 3, 2012, Pages 510-514

  Fujii, Masanori ^a,b   Fujimoto, Nobukazu ^a   Hiraki, Akio ^c   Gemba, Kenichi ^a   Aoe, Keisuke ^d   Umemura, Shigeki ^e   Katayama, Hideki ^d   Takigawa, Nagio ^b   Kiura, Katsuyuki ^b   Tanimoto, Mitsune ^b   Kishimoto, Takumi ^a  

^a OKAYAMA ROSAI HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d NATIONAL SANYO HOSPITAL   (Japan)

^e Sumitomo Besshi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; DIAGNOSTIC AGENT; DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURISY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; BODY FLUID; CHEMICALLY INDUCED DISORDER; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; MESOTHELIOMA; MIDDLE AGED; PLEURA TUMOR; PROMOTER REGION;

AGED; AGED, 80 AND OVER; ASBESTOS; BODY FLUIDS; DIAGNOSIS, DIFFERENTIAL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84859732396     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02180.x     Document Type: Article

References (36)

1. Fujimoto N, Aoe K, Gemba K, Kato K, Yamazaki K, Kishimoto T. Clinical investigation of malignant mesothelioma in Japan. J Cancer Res Clin Oncol 2010; 136: 1755-9.
2. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 1993; 72: 389-93.
3. Light R. Malignant pleural effusions. In: Retford DC, ed. Pleural Diseases, 3rd edn. Baltimore: Williams & Williams, 1995; 94-116.
4. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology 2008; 13: 518-27.
5. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang H. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 2008; 63: 35-41.
6. Aoe K, Hiraki A, Maeda T et al. Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion. Chest 2004; 126: 1195-7.
7. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 2007; 57: 190-9.
8. Scherpereel A, Grigoriu B, Conti M et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-60.
9. Fujimoto N, Gemba K, Asano M et al. Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma. Exper Ther Med 2010; 1: 313-7.
10. Hiraki A, Aoe K, Ueoka H. Asbestos exposure and serum osteopontin. N Engl J Med 2006; 354: 304-5; author reply 304-5.
11. Hino O, Maeda M. Diagnostic tumor marker of asbestos-related mesothelioma. Environ Health Prev Med 2008; 13: 71-4.
12. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10: 687-92.
13. Toyooka S, Toyooka KO, Maruyama R et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001; 1: 61-7.
14. Fujiwara K, Fujimoto N, Tabata M et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005; 11: 1219-25.
15. Umemura S, Fujimoto N, Hiraki A et al. Aberrant promoter hypermethylation in serum DNA from patients with silicosis. Carcinogenesis 2008; 29: 1845-9.
16. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002; 23: 1127-30.
17. Tsou JA, Galler JS, Wali A et al. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 2007; 58: 220-30.
18. Tsou JA, Shen LY, Siegmund KD et al. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 2005; 47: 193-204.
19. Christensen BC, Godleski JJ, Marsit CJ et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008; 29: 1555-9.
20. Katayama H, Hiraki A, Aoe K et al. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer 2007; 120: 2191-5.
21. World Health Organization. Histological typing of lungs and pleural tumors, 3rd edn. Berlin: Springer, 1999.
22. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-7.
23. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996; 14: 1-12.
24. Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA 1982; 247: 617-22.
25. Miyamoto H. Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells. Acta Med Okayama 1986; 40: 65-73.
26. Burbee DG, Forgacs E, Zochbauer-Muller S et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691-9.
27. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249-55.
28. Brock MV, Hooker CM, Ota-Machida E et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358: 1118-28.
29. Pulling LC, Divine KK, Klinge DM et al. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res 2003; 63: 4842-8.
30. Brabender J, Usadel H, Metzger R et al. Quantitative O6-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res 2003; 9: 223-7.
31. Yanagawa N, Tamura G, Oizumi H et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007; 58: 131-8.
32. Topaloglu O, Hoque MO, Tokumaru Y et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004; 10: 2284-8.
33. Toyooka S, Pass HI, Shivapurkar N et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001; 61: 5727-30.
34. Kobayashi N, Toyooka S, Yanai H et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008; 62: 120-5.
35. Eisenstadt HB. Asbestos pleurisy. Dis Chest 1964; 46: 78-81.
36. Moalli PA, MacDonald JL, Goodglick LA, Kane AB. Acute injury and regeneration of the mesothelium in response to asbestos fibers. Am J Pathol 1987; 128: 426-45.